Catalog No.: PC-21392Not For Human Use, Lab Use Only.
NUCC-555 is a selective antagonist of Activin antagonist, shows dose-dependent antagonistic activity against activin A-stimulated FSHβ promoter activation in 338FSHβ-luc LβT2 cells with IC50 of 3.67 uM.
NUCC-555 is a selective antagonist of Activin antagonist, shows dose-dependent antagonistic activity against activin A-stimulated FSHβ promoter activation in 338FSHβ-luc LβT2 cells with IC50 of 3.67 uM.
NUCC-555 binds to the activin A:ActRII that disrupts the activin A:ActRII complex's binding with ALK4-ECD-Fc in a dose-dependent manner.
NUCC-555 also specifically binds to activin A compared with other TGFβ superfamily member myostatin (GDF8).
NUCC-555 completely blocks activin A/ActRIIA complex binding with ALK4 at 25 uM, shows no blocking activity to the myostatin/ActRIIA complex binding with ALK4.
NUCC-555 not only strongly antagonizes function against activin A but also has selectivity for binding to activin A over other TGFβ superfamily members, such as myostatin.
NUCC-555 (30 or 60 mg/kg) treatment induces a dose-dependent decrease in FSH levels in ovariectomized mice.
